Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Diversified Trust Co raised its holdings in Eli Lilly and Company (NYSE: LLY) by 16.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,592 shares of the company's stock after buying an additional 2,758 shares

Calamos Advisors LLC cut its holdings in shares of Eli Lilly and Company (NYSE: LLY) by 1.5% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 274,313 shares of the company's stock after selling 4,255 shares during the period. Eli

Generate Investment Management Ltd boosted its stake in Eli Lilly and Company (NYSE: LLY) by 23.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 81,813 shares of the company's stock after buying an additional 15,352 shares during the

Ascent Group LLC lifted its position in shares of Eli Lilly and Company (NYSE: LLY) by 3.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,821 shares of the company's stock after buying an additional 575 shares during

Pfizer (PFE) and GlaxoSmithKline (GSK) are among the top drugmakers planning price increases for hundreds of branded medicines in the U.S. next year, according

Eli Lilly is working on the acquisition of a France-based drugmaker. This could allow it to expand its footprint in the immunology market.

First American Bank decreased its position in Eli Lilly and Company (NYSE: LLY) by 1.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 52,156 shares of the company's stock after selling 872 shares during the period. Eli Lilly and

Copeland Capital Management LLC lessened its holdings in shares of Eli Lilly and Company (NYSE: LLY) by 3.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,902 shares of the company's stock after selling 704 shares during the quarter. Copeland Capital Management

Fort Washington Investment Advisors Inc. OH increased its stake in shares of Eli Lilly and Company (NYSE: LLY) by 41.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,915 shares of the company's stock after buying an additional 14,301 shares during the period.